Naclerio Nicholas 的 Form 4 申報
Alamar Biosciences, Inc.(ALMR),2026/4/20 申報
- 申報編號
- 0001534166-26-000006
- 申報時間
- 2026/4/20 20:31 ET
- 交易日
- 2026/4/16-4/20
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 8 筆非衍生性交易、7 筆衍生性交易。公開市場買進合計 $400.0 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Naclerio NicholasCIK 0001534166 | 董事 |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/4/20 | Class B Common Stock | C轉換取得 | +4,588,364 | –F1 | – | 4,588,364 | 間接 | |
| 2026/4/20 | Class B Common Stock | C轉換取得 | +922,152 | –F3 | – | 5,510,516 | 間接 | |
| 2026/4/20 | Class B Common Stock | J其他處分 | −5,510,516 | –F4 | – | 0 | 間接 | |
| 2026/4/20 | Common Stock | J其他取得 | +5,510,516 | –F4 | – | 5,510,516 | 間接 | |
| 2026/4/20 | Common Stock | C轉換取得 | +346,020 | –F5 | – | 5,856,536 | 間接 | |
| 2026/4/20 | Common Stock | C轉換取得 | +271,782 | –F5 | – | 271,782 | 間接 | |
| 2026/4/20 | Common Stock | P買進取得 | +235,294 | $17.00 | +$3,999,998 | 507,076 | 間接 | |
| 2026/4/20 | Common Stock | A公司授予取得 | +5,686 | $0.00 | $0 | 5,686 | 直接 |
衍生性證券(表 II)
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/4/16 | Common Stock | A公司授予取得 | +25,599 | $0.00 | $0 | 25,599 | 直接 | |
| 2026/4/20 | Class B Common Stock | C轉換處分 | −1,321,082 | $0.00 | $0 | 0 | 間接 | |
| 2026/4/20 | Class B Common Stock | C轉換處分 | −1,183,832 | $0.00 | $0 | 0 | 間接 | |
| 2026/4/20 | Class B Common Stock | C轉換處分 | −922,152 | $0.00 | $0 | 0 | 間接 | |
| 2026/4/20 | Class B Common Stock | C轉換處分 | −2,083,450 | $0.00 | $0 | 0 | 間接 | |
| 2026/4/20 | Common Stock | C轉換處分 | −346,020 | $0.00 | – | 0 | 間接 | |
| 2026/4/20 | Common Stock | C轉換處分 | −271,782 | $0.00 | – | 0 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F1
The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the "IPO").
表 I 有 1 筆交易的價格引用這則附註。
- F3
The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
表 I 有 2 筆交易的價格引用這則附註。
- F5
Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85.
表 I 有 2 筆交易的價格引用這則附註。